Clene Inc. (CLNN) is a biotechnology company focusing on the development and commercialization of therapeutic therapies based on nanotechnologies for the treatment of neurodegenerative diseases. The company concentrates on developing therapeutic products that utilize nanocrystalline platforms to support nerve cell recovery and protection from degeneration. Clene Inc. is engaged in addressing diseases like amyotrophic lateral sclerosis (ALS) and other neurodegenerative disorders. With the growing awareness of the need for neurodegenerative disease treatment, Clene Inc. has the potential for sustained growth. Clene Inc. (CLNN) shares might be an interesting choice for investors seeking involvement in the biotechnology and therapeutic therapies for neurodegenerative diseases.